Endometrial safety assessment of a specific and standardized soy extract according to international guidelines

Menopause

Volumn 14, Issue 6, 2007, Pages 1006-1011

  Palacios, Santiago ^a   Pornel, Bruno ^b   Bergeron, Christine ^c   Chantre, Philippe ^d,i   Nogales, Francisco ^e   Aubert, Laurence ^d   Vazquez, Francisco ^f   Eden, John ^g   Mares, Pierre ^h  

^a Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^b Brussels Menopause Center   (Belgium)

^c LABORATOIRE CERBA   (France)

^d Laboratoires Arkopharma   (France)

^e UNIVERSITY OF GRANADA   (Spain)

^f Clínica de Ginecología CEOGA   (Spain)

^g Sydney Menopause Centre   (Australia)

^h DEPARTMENT OF NEUROLOGY   (France)

ⁱ Laboratoires Arkopharma   (France)

Author keywords

Endometrial safety; Isoflavones; Menopause

Indexed keywords

DAIDZIN; GENISTIN; GLYCITIN; ISOFLAVONE; ISOFLAVONE DERIVATIVE; SOY ISOFLAVONE EXTRACT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; CELL PROLIFERATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ECHOGRAPHY; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RISK ASSESSMENT; SOYBEAN; TREATMENT DURATION;

ADMINISTRATION, ORAL; ENDOMETRIUM; EUROPE; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; PHYTOESTROGENS; PHYTOTHERAPY; PLANT EXTRACTS; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; SOYBEANS;

EID: 36049048927     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3180590c42     Document Type: Article

References (40)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44.
3. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
4. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115.
5. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
6. Stefanik ML, Anderson GL, Margolis KL, et al. Effects of conjugated estrogens on breast cancer and mammary screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
7. The North American Menopause Society. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society. Menopause 2003;10:113-132.
8. Kuiper G, Carlsonn B, Grandien K. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-870.
9. Committee for Proprietary Medicinal Products. Points to Consider on Hormone Replacement Therapy. EMEA/CHMP/021/97. London, UK: Committee for Propietary Medicinal Products, 1997.
10. Committee for Medicinal Products for Human Use. Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Deficiency Symptoms in Postmenopausal Women. EMEA/CHMP/01/97 rev1. London, UK: Committee for Medicinal Products for Human Use, 2006.
11. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-1748.
12. Grady O, Gebretsadik T, Ernster K, Petitti V. Hormonal replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
13. Personn I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with estrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-151.
14. Personn I, Yven J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-332.
15. Wasburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999;6:7-13.
16. Brzezinski A, Adlercreutz, Shaoul R, et al. Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause 1997;4:89-94.
17. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998;91:6-11.
18. Scambia G, Mango D, Signorile P, et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000;7:105-111.
19. Upmalis D, Lobo R, Bradley L, Warren M, Cone F, Lamia C. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicentre, double-blind, randomized, placebo-controlled study. Menopause 2000;7:236-242.
20. Drapier Faure E, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9:329-334.
21. Chen YM, Ho SC, Lam SS, Jo SS, Woo JL. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind randomized, controlled trial. J Clin Endocrinol Metab 2003;88:4740-4747.
22. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. Menopause 2004;11:290-298.
23. Morabito N, Crisaffuli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002;17:1904-1912.
24. Potter SM, Baum JA, Teng HY, Stillman RJ, Shay NF, Erdman JW. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68:1375S-1379S.
25. Anthony MS, Clarkson TB, Hugles CL, Moragan TM, Burke GL. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr 1996;126:43-50.
26. Crouse JR, Morgan TM, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999;159:2070-2076.
27. Greaves KA, Wilson MD, Rudel LL, William JK, Wagner JD. Intact dietary soy protein, but not adding an isoflavone-riche soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. J Nutr 1999;129:1585-1592.
28. Nestel PF, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesaroff P. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997;17:392-398.
29. Pan Y, Anthony M, Watson S, Clarkson TB. Soy phytoestrogens improve radial arms maze performance in ovariectomized retired breeder rats and do not attenuate benefits of 17-β estradiol treatment. Menopause 2000;7:230-235.
30. Foth D, Cline JM. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 1998;68(6 Suppl):1413S-1417S.
31. Balk JL, Whiteside DA, Naus G, De Ferrari E, Roberts JM. A pilot study of effects oh phytoestrogens supplementation on postmenopausal endometrium. J Soc Gynecol Investig 2002;9:238-242.
32. Perrotti M, Fabio E, Modena AB, Rinaldi M, Omodu U, Vignano P. Effects of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril 2003;79:1112-1117.
33. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000;7:236-242.
34. Sammartino A, Di Carlo C, Mandato VD, Bifulco G, Di Stefano M, Nappi C. Effects of genistein on the endometrium: ultrasonographic evaluation. Gynecol Endocrinol 2003;17:45-49.
35. Unfer V, Casini ML, Castabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004;82:145-148.
36. Gredmark T, Kvint S, Havel G, Mattsson L. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol 1995;102:133-136.
37. Ginsbourg J, Prelevic GM. Cause of vaginal bleeding in postmenopausal women taking tibolone. Maturitas 1996;24:107-110.
38. Houriban HM, Sheppard BL, Bomar J. A morphometric study of the effect of oral norethisterone or levonorgestrol on endometrial blood vessels. Contraception 1986;34:603-612.
39. Presta M. Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. J Cell Physiol 1988;137:593-597.
40. Torry DS, Holt VJ, Keenan JA, Harris G, Caudle MR, Torry RJ. Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 1996;66:72-80.